Initially, we determined the expression of the C-MYC (WT1) oncogene in primary patients with AML (n = 44) belonging to two different patient groups: FLT3-ITD-negative (n = 30) and FLT3-ITD-positive (n = 14). Here, MYC is linked to acute myeloid leukemia.